EUR/USD 1.16417
0.091%
Gold 4506.58
0.488%
Oil 90.020
-0.991%
USD/JPY 159.864
0.124%
GBP/USD 1.34782
0.177%
GBP/JPY 215.473
0.302%
Browse More
  • English
  • 简体中文
  • 繁體中文
  • Tiếng Việt
  • ไทย
  • Indonesia
Subscribe
Real-time News
1. According to the Financial Times, Abu Dhabi National Oil Company plans to build an oil product pipeline bypassing the Strait of Hormuz. 2. According to foreign media reports, a joint statement shows that Indonesian business groups are calling on the government to issue technical guidelines for its plans to centralize exports and retain export profits in state-owned banks. The Indonesian Employers Association, along with the Miners, Coal Miners, Nickel Smelters, and Palm Oil Producers Association, stated that they support the new regulations but hope the government will cooperate with the private sector in their implementation. 3. According to CCTV News, on the 2nd local time, Israeli sources reported that the fourth round of Israel-Lebanon talks was held in Washington, D.C. 4. According to Iranian media Fars News, an informed source revealed that although some Western media and officials have attempted to describe the information exchange process between Iran and the United States as normal, there is currently no information exchange between the two sides. Information exchanges between Iran and the United States aimed at reaching a preliminary memorandum of understanding have been interrupted for at least several days. 5. Federal Reserves Hamak stated that inflation may require policy assistance to reach 2%; if the inflation trend does not cool, the Fed may need to act "as soon as possible"; maintaining stable interest rates is reasonable at present, but if high inflation persists, a larger adjustment may be needed; there are no signs of rising inflation expectations. 6. According to the European Commission, as of May 31, the EUs palm oil imports for 2025/26 were 2.6 million tons, compared to 2.75 million tons in the same period last year. The EUs soybean imports for 2025/26 were 12.38 million tons, compared to 13.32 million tons last year. 7. Iranian media reported on the 2nd that the application system for ship passage permits in the Strait of Hormuz is now fully open, allowing ship owners and captains worldwide to submit applications at any time of day, 24 hours a day. 8. The World Meteorological Organization issued a bulletin on the 2nd stating that considering factors such as unusually warm tropical Pacific Ocean waters, the probability of an El Niño event occurring from June to August is 80%, and the risk of extreme weather in the coming months is rising accordingly. 9. According to Dan Struven, co-head of global commodities research at Goldman Sachs, if commercial crude oil inventories continue to decline at the recent rate with the Strait of Hormuz almost completely closed, U.S. diesel inventories could fall to a critical level by August, enough to sustain only 20 days of supply. 10. U.S. JOLTs job openings surged in April, rising to 7.62 million from 6.89 million in March, reaching the highest level in nearly two years, while layoffs decreased. These signs indicate that the labor market remains strong despite pressure from rising energy costs due to the war with Iran.Bank of England Governor Bailey: Not all AI-related stocks will be winners.US Secretary of State Rubio: Iran will not receive the lifting of sanctions simply because the Strait of Hormuz has been reopened.U.S. Secretary of State Marco Rubio: Any reduction or easing of sanctions on Iran will be contingent upon the fulfillment of relevant conditions.Bank of England Governor Bailey: It is necessary to maintain the labor supply to promote economic growth.

AstraZeneca's Breast Cancer Medication Could Be Used More Widely After New Results

Charlie Brooks

Jun 06, 2022 10:56

3.png


According to data published on Sunday, AstraZeneca (NASDAQ:AZN) and Daiichi Sankyo's Enhertu increased survival by more than six months in patients with advanced breast cancer compared to usual chemotherapy.


The data, which was presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago, might open a big, new multibillion-dollar patient group for the medicine that received U.S. approval late in 2019 for the 15 percent of breast cancer patients with HER2-positive illness.


Over 550 patients with so-called HER2-low breast cancer - the majority with hormone-sensitive tumors - whose disease had progressed and who had completed at least one round of chemotherapy are participating in the ongoing phase III research.


The interim analysis revealed that Enhertu increased survival by an extra 6,4 months in hormone-sensitive tumor patients. The group had a median survival rate of 23.9 months, compared to 17.5 months for chemotherapy patients.


In the small sample of patients with hormone-resistant tumors, Enhertu improved survival by 6.3 months.


David Fredrickson, executive vice president of AstraZeneca's oncology unit, expressed surprise to Reuters that the improvement in overall survival was obvious even at the interim analysis point.


This provides a great deal of assurance that the benefit we are observing here is genuine.


The prognosis for individuals with advanced HER2-positive breast cancer has been vastly improved by a variety of targeted therapy. More than half of women whose breast cancer has progressed to other organs and express little or no HER2 have restricted therapeutic options; this is known as HER2-low status.


It was statistically significant that hormone-sensitive patients who got Enhertu had a progression-free survival (PFS) of 10.1 months on average, compared to 5.4 months for chemotherapy.


Enhertu more than doubled the PFS for hormone-insensitive individuals, from 2.9 months with chemotherapy to 6.6 months with Enhertu.


AstraZeneca is in talks with regulators worldwide regarding authorisation for the HER2-low population. Analysts at Jefferies predicted last month that annual global peak sales of Enhertu for these patients would reach $2.5 billion, and around $6.6 billion for all indications.


There are safety issues with the medicine, which is provided by intravenous infusion. It has been associated with interstitial lung disease, a form of lung scarring (ILD). In the trial, 45 Enhertu patients developed varied degrees of ILD, compared to one patient in the chemotherapy group.


Enhertu is part of a therapeutic class known as antibody drug conjugates (ADC), which are designed antibodies that bind to cancer cells and release cell-killing chemicals.


A study showed that it lowered the risk of disease progression or death by 72% when compared to Roche's Kadcyla, the standard treatment. It was approved as a second-line treatment option last month.


Enhertu is being studied for usage in breast cancer's earliest stages, as well as lung and colorectal malignancies. It has been approved for HER2-positive stomach cancer.


Reuters quoted Tara Hansen, a consultant at Informa Pharma Custom Intelligence, as saying, "As far as breast cancer is concerned, I'm rather certain that Enhertu will finish revolutionizing the therapy paradigm over the next five years."


In 2021, Enhertu generated $214 million in revenue. Three years ago, AstraZeneca acquired partial rights to the Daiichi Sankyo chemical in a deal valued up to $6.9 billion.


Suggestion